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Pharmacological evaluation of a phytotherapeutic product - CPV 
(dry extract of Crataegus oxyacantha L., Passiflora incarnata L. 
and Valeriana officinalis L.) in laboratory animals
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RESUMO: “Avaliação farmacológica do produto fitoterápico – CPV (extrato seco de 
Crataegus oxyacantha L., Passiflora incarnata L. e Valeriana officinalis L.) em animais de 
laboratório”. O presente estudo teve por objetivo avaliar em modelos animais, os possíveis 
efeitos do produto fitoterápico CPV (extrato seco de Crataegus oxyacantha, Passiflora	incarnata 
e Valeriana	officinalis) quanto à sua ação ansiolítica avaliada no modelo do labirinto em cruz 
elevado (LCE). Outros efeitos como neuroléptico (bloqueio da estereotipia por apomorfina), 
analgésico (testes: placa quente; retirada da cauda e contorções abdominais), bem como sobre 
a memória (esquiva passiva) também foram considerados. O extrato CPV (430 e 860 mg/kg) 
apresentou um efeito ansiolítico (aumento do número de entradas nos braços abertos do LCE) 
em ratos e uma tendência de efeito amnésico para ambas as doses (430 e 860 mg/kg), embora 
menos intenso quando comparado com o diazepam (1,5 mg/kg). O extrato não apresentou efeitos 
neuroléptico ou analgésico.
Unitermos: Passiflora	incarnata,	Crataegus	oxyacantha,	Valeriana	officinalis, Passifloraceae, 
Rosaceae, Valerianaceae, atividade ansiolítica, SNC.
ABSTRACT: The aim of the present study was to evaluate the central effects of the 
phytotherapeutic product-CPV (dry extract of	Crataegus	oxyacantha,	Passiflora	incarnata	and 
Valeriana	 officinalis) in animals models. In order to investigate the psychopharmacological 
profile of CPV extract, an evaluation toward anxiolytic effect of this extract on the elevated 
plus-maze (EPM) was carried out. Other effects such as neuroleptic (blockade of the stereotyped 
behavior induced by apomorphine), analgesic (hot plate; acetic acid writhing and tail-flick tests) 
and on the memory (passive avoidance test) were also analyzed. CPV extract (430 and 860 mg/
kg) presented an anxiolytic effect on rats (increased the number of entries into the open arms 
in the EPM) and, furthermore, a tendency of slight amnesic effect for the doses (430 and 860 
mg/kg), but less intense when compared to diazepam (1.5 mg/kg). The extract did not show 
neuroleptic or analgesic effects.
Keywords: Passiflora	incarnata,	Crataegus	oxyacantha,	Valeriana	officinalis, Passifloraceae, 
Rosaceae, Valerianaceae, anxiolytic effects, CNS.
INTRODUCTION
 The association of various plants in a single 
medication is a relatively common practice in several 
countries. As examples, in France, Euphytose®, 
an association of Passiflora	 incarnata,	 Valeriana	
officinalis,	 Crataegus	 oxyacantha, and three other 
plants, has been used for its anxiolytic properties (Valli 
et al., 1991). In Chinese therapeutics, the practice of 
associating various plants with a view to producing 
one specific therapeutic effect is widely known (Yuan 
and Lin, 2000). Authors suggest that these associations 
may result, indeed, in a better therapeutic effect when 
compared with each plant or even when compared 
to one active principle (Gilbert and Alves, 2003). 
The pharmacological effects attributed separately 
to each plant of a phytotherapeutic product - CPV 
(dry extract of Crataegus	 oxyacantha	 L.,	 Passiflora	
incarnata	 L., and	 Valeriana	 officinalis	 L.) are well 
described in the literature. For instance, P.	 incarnata 
exerts anxiolytic, sedative and anticonvulsant 
actions (Speroni et al., 1996; Dhawan et al., 2001; 
Quintans-Júnior et al., 2008), C.	oxyacantha possesses 
cardiotonic, antiatherogenic, and antioxidant effects, 
which would enhance its action on atherosclerosis 
(Shanthi et al., 1996) and V.	 officinalis	was utilized 
traditionally as a sedative for light insomnia, in 
addition to being indicated for its anxiolytic properties 
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when administered in smaller doses (Morazzoni & 
Bombardelli, 1995; Cropley et al., 2002; Sousa et 
al., 2008). Its pharmacological effects are attributed 
to the presence of valepotriates and sesquiterpenes 
that would act on the GABA system (Yuan et al., 
2004). This may account for its pharmacological 
effects on anxiety and depression (Santos et al., 
1994). However, studies should be developed with a 
view to demonstrating that an association of plants 
will not produce any posterior toxic effects, possibly 
inexistent in individual components and, in addition, 
that the association will not annul the effects for 
which individual plants are utilized, nor give rise to 
unexpected effects. In a previous study with animals, 
carried out in our laboratory, it was verified that 
CPV extract did not produce toxicity worthy of note, 
even when administered in high doses and for a long 
period of time (Tabach et al., 2008). In the present 
study the possible central effects of the CPV extract 
were investigated with a view to establishing the 
psychopharmacological profile mainly in that which 
concerns a possible anxiolytic effect. We endeavored 
to verify, concomitantly, whether the extract might 
produce any other effect neuroleptic, analgesic, or 
exerts any effect on memory.
MATERIAL AND METHODS
Animals
 Male albino Swiss mice, (3 to 4 months of age), 
weighing 30 - 40 g and male Wistar rats (3 months 
of age) weighing 300 - 400 g were obtained from the 
Department of Psychobiology, UNIFESP. Animals 
were maintained at constant room temperature (23 ± 
1 ºC) with a 12L:12D light schedule (lights on 6:00 
a.m. to 6:00 p.m.) and free access to food and water. 
All the experiments were carried out in accordance to 
the norms of the Ethics Committee for Research of the 
Universidade Federal de São Paulo (CEP nº: 1400/01). 
The animals used in this study were maintained in 
accordance with the guidelines of the Committee 
on Care and Use of Laboratory Animal Resources, 
National Research Council, USA.
Botanical material
The CPV extract consists in material obtained 
from: C.	 oxyacantha (Rosaceae), known in Brazil 
as “pilriteiro”, a hawthorn a shrub native to Europe 
(Rigelsky and Sweet, 2002; Brandão et al., 2006); P.	
incarnata (Passifloraceae), known as maracujá, passion 
fruit, a creeper native to Tropical America (Soulimani 
et al., 1997; Marliére et al., 2008) and V.	 officinalis 
(Valerianaceae) a perennial plant, native to Europe and 
Western Asia (Morazzoni et al., 1995). The dry extracts 
of C.	 oxyacantha	 (batch n° 04804/M1),	 P.	 incarnata 
(batch n° 04675/M1) and	V.	officinalis	(batch n° 26961/
M2) were purchased by Biolab Sanus Farmacêutica 
Ltda. from Indena®, having been identified 
through high efficiency liquid chromatography and, 
subsequently, assessed as to their physicochemical 
characteristics, residual contamination by organic 
solvents, and microbiological contamination following 
standards of reference, in accordance to the official 
reports supplied by Indena® (analysis certificates 
numbers 11580 C.	oxyacantha, 11636 P.	incarnata and 
62706 V.	officinalis). These extracts were mixed in the 
following proportion: C.	oxyacantha: 0.8 kg (26.7%), 
P.	 incarnata: 1.0 kg (33.3%) and V.	 officinalis: 1.2 
kg (40%). This proportion was chosen based on the 
composition of a most used marketed product in Brazil 
that possesses the same amounts of the three extracts.
Drugs
Apomorphine hydrochloride; scopolamine 
bromide, morphine sulfate and pentylenetetrazol 
(Sigma Chemical Co St Louis, USA); diazepam 
(Roche do Brazil).
Extract administration
The CPV extract, diluted in water as needed, was 
administered either through oral or ip (intraperitoneal) 
routes in constant volume of 0.1 mL/ 10g of weight 
in mice and 0.1 mL/100 g of weight in rats. Different 
concentrations of the extracts were used in order to 
obtain the desired dosage (mg/kg) for the animals; in 
all cases, a very fine stable suspension was obtained. 
The doses employed in the rats were based on the 
human daily dosage of the marketed phytomedicine 
available in Brazil (a pill of 300 mg corresponding to 
4.3 mg/kg for an adult of 70 kg; doses 100 and 200 
times larger were also employed).
Evaluation of the anxiolytic effect
Elevated plus- maze (EPM)
 The maze consists of two open arms and two 
closed arms by 30 cm high walls. Each arm measures 50 
cm of length by 10 cm of width and contains a central 
square of 10 x 10 cm. The maze was 60 cm above the 
floor. Four groups of 10 animals each, being them 
control (water, oral), diazepam (1.5 mg/kg, ip), and 
CPV extract (430 and 860 mg/kg, oral), were placed in 
the center of the maze and recorded the number of times 
they entered the open and closed arms, as well as how 
long they stayed there within 5 min. In order to evaluate 
their level of emotionality, we considered their number 
of entries in the open arms and the time they remained 
there: the higher the number, the lower their level of 
emotionality (Pellow et al., 1985; Fenner, et al., 2008).
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Table 1. Time of latency for clonic and tonic convulsions induced by 100 mg/kg of pentylenetetrazol in mice.
Treatment Dose
(mg/kg)
Clonic convulsions (latency 
in min)
Tonic convulsions (latency in min)
Control --- 4.9 ± 1.7 10.5 ± 7.2
CPV Extract 430 3.3 ± 3.0     5.6  ± 4.1*
CPV Extract 860 3.4 ± 2.9    9.1  ±  4.0
(*) p < 0.05 differs in relation to control. (ANOVA / Duncan’s test).
Table 2. Effects of CPV extract on a stereotype behavior induced by 5 mg/kg (ip) of apomorphine over the course of time.
Treatment Degrees of stereotype behavior over the course of time(median ± interquartile)
Groups Dose (mg/kg) 5 min 15 min 30 min 45 min 60 min
Control --- 3.0 ± 0 5.0 ± 1 7.0 ± 3 6.0 ± 2 4.0 ± 2
CPV Extract 430 4.0 ± 0.5 5.5 ± 1 7.0 ± 0.5 7.0 ± 0 4.0 ± 4
CPV Extract 860 3.5 ± 2 6.5 ± 1.5 7.0 ± 1.5 6.0 ± 2 5.5 ± 3.5
NS (p > 0.05, ANOVA).
Table 3. Measurement of analgesic effect of CPV extract in mice, assessed by: a) hot plate test; b) induction of writhing by 
acetic acid; c) tail-flick test.
Treatments
a) Time (s) of
permanence on hot
plate (x ± dp)
b) Number  of 
writhing	
( x ± dp)
c) Time (s) for removal of tail (tail-
flick) (x ± dp)
Groups Dose (mg/
kg)
30 min 60 min Amount 30 min 60 min
Control --- 8.2 ± 3.1 9.8 ± 4.3 7.1 ± 3.1 2.8 ± 1.7 2.7 ± 1.0
Morphine 10 22.4 ± 7.6* 18.9 ± 7.4* 1.7 ± 2.2* 4.9 ± 5.3 4.5 ± 2.9*
CPV Extract 1.250 15.0 ± 9.3 15.1 ± 7.1 6.1 ± 3.5 1.7 ± 1.0 2.9 ± 0.8
CPV Extract 2.500 11.8 ± 37 9.2 ± 3.4 6.2 ± 2.6 2.6 ± 1.2 4.1 ± 2.4
(*) p < 0.05 compared with control. (ANOVA/Duncan’s test).
Antipentylenetetrazol effect
Three groups of 10 mice each were given 
water (control) or CPV extract (430 and 860 mg/
kg), by mouth. After 60 min, the animals were given 
pentylenetetrazol (100 mg/kg, sc), and the latency 
time for the onset of clonic or tonic convulsions was 
observed (Mattei et al., 1995).
Other pharmacological effects
Effect on memory and learning	 (Passive avoidance 
test)
Three groups of 10 mice each, being them control 
(water, oral) and CPV extract (430 and 860 mg/kg, 
oral) were administered. After 30 min the animals 
were given a dose of scopolamine (0.5 mg/kg, ip) 
30, and were subjected to the test after 30 min. The 
passive avoidance task was measured in an apparatus 
consisting of one light and one dark compartment. 
After treatment, each animal was placed in the light 
compartment and the time was measured of how long 
it took to move into the dark compartment (acquisition 
latency). A shock of 1.0 mA/2s was applied as soon 
as the animal stepped into the dark compartment. 
Immediately after that the animals returned to its 
homecage and 24 h later, replaced into the light 
compartment in order to measure the time it took to 
move from the light side into the dark one (retention 
latency). Animals that did not enter after 180s were 
removed from the apparatus, and 180 s were noted as 
time of retention (Galvão et al., 2002).
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Figure 1. Number of entrances (A) and time (s) of permanence 
(B) on the open and closed arms of rats orally treated with 
water (control), CPV extract (430 and 860 mg/kg) and 
diazepam (1.5 mg/kg). The values are expressed by means 
± standard error (SEM). (*) Difference between control and 
other groups. p < 0.05 (ANOVA/Duncan’s test).
Figure 2. Latency of acquisition and retention at the passive 
avoidance test of mice orally treated with: water (control), 
CPV extract (430 and 860 mg/kg) and diazepam (1.5 mg/kg). 
The values are expressed by means ± standard error (SEM). 
(*) Difference between control and other groups p < 0.05 
(Kruskall-Wallis/Mann-Whitney Test).
Neuroleptic effect
Blockade of the stereotyped behavior induced by 
apomorphine
Three groups of 10 rats each, being them control 
(water, oral) and CPV extract (430 and 860 mg/kg, 
oral), were placed individually in wire cages and, 
after 30 min, were given apomorphine (5 mg/kg, ip). 
They were observed for 60 min and the degrees of 
stereotyped behavior recorded (Galvão et al., 2005).
Analgesic effect
Hot plate test
Four groups of 10 mice each received water 
(control, oral) and CPV extract (430 and 860 mg/kg, 
oral). A positive control was given morphine (10 mg/
kg). The animals were subjected to the test before 
(basal) and after 15, 30, 60, and 120 minutes from 
administering, measuring reaction time to thermal 
stimulus (55 ºC) characterized by the animal’s reaction 
in “dancing” on the plate and/or licking its paws. A 
maximum of 30 s. was established to prevent damage 
to the animal’s paws (Mendes et al., 2002).
Acetic acid writhing test
Four groups of 10 mice each were given water 
(control, oral), morphine (10 mg/kg, ip), and CPV 
extract (430 and 860 mg/kg, oral). After 30 minutes, 
they were injected with acetic acid (0.6% ip). The 
cumulative number of writhing responses (abdominal 
constriction) was recorded for 30 min (Perazzo et al., 
2008).
Tail-flick test
Four groups of 10 rats each were given water 
(control, oral), morphine (10 mg/kg ip), and CPV 
extract (430 and 860 mg/kg, oral). The animals were 
subjected to the test before (basal) and after 15, 30, 
60, and 120 minutes from administering, measuring 
the latency for removing the tail positioned on a 
bulb projecting heat previously adjusted to produce a 
basal reaction time between 4 and 6 s. The reflex for 
removing the tail was automatically measured through 
a photodetector up to a maximum of 15 s. (Mendes et 
al., 2002; Perazzo et al., 2008).
Statistical analysis
The data obtained from the passive avoidance 
were analyzed by the Kruskal-Wallis Test followed 
by the Mann-Whitney U Test. The results obtained 
with the other tests were subjected to an Analysis of 
Variance (ANOVA) followed by the Duncan’s Test. 
Differences were considered statistically significant 
when p ≤ 0.05.
RESULTS
Evaluation of the anxiolytic effect
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CPV extract, at the doses of 430 and 860 mg/
kg, increased the number of entrances of the animals 
into the open arms of the EPM and these results were 
statistically different when compared to the control 
group (Figure 1A). There was a tendency (p = 0.057) for 
the experimental animals (CPV 860 mg/kg) to remain 
longer in the open arms when compared to the control 
group (Figure 1B). These parameters are indicative of 
the degree of emotionality of the animals, suggesting 
an anxiolytic effect from CPV extract (Pellow et al., 
1985). Diazepam, at the dose of 1.5 mg/kg, increased 
both the number of entrances and the time spent on 
the open arms in a statistically significant way (Figure 
1A, 1B). 
The time of latency for clonic and tonic 
convulsions induced by 100 mg/kg of pentylenetetrazol 
in experimental group was similar to control group, 
except for the latency to tonic convulsions with 460 
mg/kg of CPV (Table 1).
Other pharmacological effects
The results obtained in the passive avoidance 
test showed that diazepam induced a statistically 
significant worsening in the memory of the animals 
(Figure 2), in such a way that, when they were 
placed in the apparatus in which they had been given 
shocks the previous day, they moved, quickly, to 
the side where they had received the shock 24 hours 
previously. The doses of 430 and 860 mg/kg of CPV 
also presented results in the same direction, which, 
however, did not attain statistical significance; in fact, 
both the comparison of control versus CPV 430 mg/kg 
(p ≤ 0.13) and the comparison control versus CPV 860 
mg/kg (p ≤ 0.57) seem to indicate an effect so similar 
to diazepam that there was no statistically significant 
difference between the 3 treatments.
CPV extract was not successful at blocking the 
stereotyped behavior produced by apomorphine (Table 
2) and did not per se induce catalepsy, nor block this 
behavior when induced by haloperidol (data not shown 
were observed).
CPV extract was not effective at blocking the 
nociceptive effect (Table 3) induced by heat (hot plate 
and tail-flick tests) or by peritoneal irritation (injection 
of acetic acid intraperitoneally). Morphine, positive 
control, showed a clear analgesic effect in these 3 tests.
DISCUSSION
Several authors have supported the point of 
view that the use of plant extracts, whether singly 
or associated, within a single medication, may have 
better therapeutic effects than the individual use of the 
isolated active principle(s); these authors postulate that 
this synergism is the result of pharmacokinetic and/or 
pharmacodynamic factors (Williamson, 2001; Gilbert 
and Alves, 2003). In this respect, the properties of two 
of the plants that make up the phytotherapeutic product 
under study should be emphasized: valepotriates 
present in V.	officinalis reverted the anxiety of the rats 
at the EPM during diazepam abstinence (Andreatini 
et al., 2002) and the anxiolytic effects of this plant 
on human beings were also observed (Poyares et 
al., 2002). P.	 incarnata has anxiolytic and sedative 
properties attributed to the presence of flavonoids and 
alkaloids exerting action on benzodiazepinic receptors 
(Speroni et al., 1996; Bourin, et al., 1997). The three 
plants that make up CPV extract are also part of two 
commercial products that are utilized therapeutically 
as anxiolytics (Hiller and Zetler, 1996). However, the 
CPV extract did not protect mice from tonic or clonic 
convulsions induced by pentylenetetrazol. It is of 
interest to note that both V.	officinalis and P.	edulis do 
not protect mice from convulsion by pentylenetetrazol 
(Valle and Leite, 1983; Hiller and Zetler, 1996). 
In synthesis, the present study shows that CPV 
extract was successful in reducing the anxiety of the 
animals when assessed in the EPM. This anxiolytic 
effect is also present in isolated extracts from at least 
two of the plants, Passiflora (Bourin et al., 1997) 
and Valeriana (Andreatini et al., 2002). Similarly to 
diazepam and other benzodiazepines (Schweizer and 
Rickels, 1997), CPV extract also proved to exert an 
amnesic effect, although less intense than produced 
by diazepam, which might be an advantage from 
the therapeutic point of view. Therefore, presents a 
pharmacological profile similar to that of diazepam, 
and does not present a neuroleptic, or analgesic effect.
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